Endo International (NASDAQ:ENDP) (TSE:ENL) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share guidance of $2.65-2.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.60. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.81 billion.Endo International also updated its FY 2018 guidance to $2.65-2.75 EPS.
NASDAQ:ENDP opened at $13.49 on Friday. Endo International has a 52 week low of $5.27 and a 52 week high of $18.50. The company has a market cap of $3.59 billion, a P/E ratio of 3.51, a PEG ratio of 1.54 and a beta of 0.65.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 8th. The company reported $0.71 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.12. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The company had revenue of $745.00 million during the quarter, compared to analysts’ expectations of $694.93 million. During the same quarter in the prior year, the company posted $0.91 earnings per share. Endo International’s revenue for the quarter was down 5.3% compared to the same quarter last year. As a group, equities analysts forecast that Endo International will post 2.68 EPS for the current fiscal year.
A number of equities research analysts recently commented on ENDP shares. Mizuho increased their target price on shares of Endo International to $17.00 and gave the company a neutral rating in a research report on Tuesday, August 14th. TheStreet raised shares of Endo International from a d rating to a c- rating in a research report on Monday, August 20th. Zacks Investment Research raised shares of Endo International from a hold rating to a buy rating and set a $18.00 target price for the company in a research report on Monday, September 24th. Cantor Fitzgerald increased their target price on shares of Endo International from $12.00 to $18.00 and gave the company a neutral rating in a research report on Friday, October 19th. Finally, Citigroup upped their price target on shares of Endo International from $11.00 to $19.00 and gave the company a buy rating in a research note on Thursday, August 9th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of Hold and an average target price of $14.97.
In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total transaction of $414,576.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Endo International (ENDP) Updates FY18 Earnings Guidance” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/11/10/endo-international-endp-updates-fy18-earnings-guidance.html.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.